Moderna COVID Vaccine Still Has 'Best-In-Class Potential,' Says Barclays

Barclays analyst Gena Wang raised the firm's price target on Moderna to $84 from $68 and keeps an Overweight rating on the shares.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.